# 1 Research Article

- 2
- 3 An herbal drug combination identified by knowledge graph alleviates the clinical
- 4 symptoms of plasma cell mastitis patients: a nonrandomized controlled trial
- 5
- Caigang Liu<sup>1,\*</sup>, Hong Yu<sup>1,#</sup>, Guanglei Chen<sup>1,#</sup>, Qichao Yang<sup>2</sup>, Nan Niu<sup>1</sup>, Ling Han<sup>3</sup>,
  Dongyu Zhao<sup>4</sup>, Manji Wang<sup>5,\*</sup>, Yuanyuan Liu<sup>6</sup>, Yongliang Yang<sup>2,\*</sup>,
- 8
- 9 <sup>1</sup>Cancer Stem Cell and Translation Medicine Lab, Innovative Cancer Drug Research
- 10 and Development Engineering Center of Liaoning Province, Department of Oncology,
- 11 Shengjing Hospital of China Medical University, Shenyang, 110004, China;
- <sup>12</sup> <sup>2</sup>School of Bioengineering, Dalian University of Technology, Dalian, 116023, China;
- 13 <sup>3</sup>National Engineering Research Center of Pharmaceutics of Traditional Chinese
- Medicine, China Resources Sanjiu Medical & Pharmaceutical Co., Ltd, Shenzhen,
  China;
- <sup>4</sup>International Cancer Institute, Peking University Health Science Center, Peking
- 17 University, Beijing, 100191, China;
- <sup>5</sup>Shanghai BeautMed Corporation, Shanghai, 200030, China;
- <sup>6</sup>Department of Biology, University of Copenhagen, Denmark.
- 20
- 21 Word count of the manuscript text: 3,645
- 22
- <sup>#</sup>These authors contributed equally to the work.
- <sup>\*</sup>To whom correspondence may be addressed:
- 25 Caigang Liu, E-mail: angel-s205@163.com; Address: Department of Oncology,
- 26 Shengjing Hospital of China Medical University, Shenyang, 110004, China (lead
- 27 contact)
- 28 Manji Wang, E-mail: 147304368@qq.com
- 29 Yongliang Yang, E-mail: everbright99@foxmail.com
- 30
- 31

# 32 Abstract

#### 33 Background

Plasma cell mastitis (PCM) is a nonbacterial breast inflammation with severe and intense clinical manifestation yet treatment methods for PCM are still rather limited. Although the mechanism of PCM remains unclear, mounting evidences suggest that the dysregulation of immune system is closely associated with the pathogenesis of PCM. Drug combinations or combination therapy could exert improved efficacy and reduced toxicity through hitting multiple discrete cellular targets.

40 *Methods* 

We have developed a knowledge graph architecture towards immunotherapy and systematic immunity that consists of herbal drug-target interactions with a novel scoring system to select drug combinations based on target-hitting rates and phenotype relativeness. To this end, we employed this knowledge graph to identify an herbal drug combination for PCM and we subsequently evaluated the efficacy of the herbal drug combination in clinical trial

# 47 Results

48 Our clinical data suggests that the herbal drug combination could significantly reduce
49 the serum level of various inflammatory cytokines, downregulate serum IgA and IgG
50 level, reduce the recurrence rate and reverse the clinical symptoms of PCM patients
51 with improvements of general health status.

52 *Conclusions* 

53	In summary, we reported that an herbal drug combination identified by knowledge
54	graph can alleviate the clinical symptoms of plasma cell mastitis patients. We
55	demonstrated that the herbal drug combination holds great promise as an effective
56	remedy for PCM, acting through the regulation of immunoinflammatory pathways
57	and improvement of systematic immune level. In particular, the herbal drug
58	combination could significantly reduce the recurrence rate of PCM, a major obstacle
59	for PCM treatment. Our data suggests that the herbal drug combination is expected to
60	feature prominently in future PCM treatment.
61	Funding
62	C. Liu's lab was supported by grants from the Public Health Science and Technology
62 63	C. Liu's lab was supported by grants from the Public Health Science and Technology Project of Shenyang (Grant: 22-321-32-18); Y. Yang's laboratory was supported by
63	Project of Shenyang (Grant: 22-321-32-18); Y. Yang's laboratory was supported by
63 64	Project of Shenyang (Grant: 22-321-32-18); Y. Yang's laboratory was supported by the National Natural Science Foundation of China (Grant: 81874301), the
63 64 65	Project of Shenyang (Grant: 22-321-32-18); Y. Yang's laboratory was supported by the National Natural Science Foundation of China (Grant: 81874301), the Fundamental Research Funds for Central University (Grant: DUT22YG122) and the
63 64 65 66	Project of Shenyang (Grant: 22-321-32-18); Y. Yang's laboratory was supported by the National Natural Science Foundation of China (Grant: 81874301), the Fundamental Research Funds for Central University (Grant: DUT22YG122) and the Key Research project of 'be Recruited and be in Command' in Liaoning Province

70 Key Words: Plasma cell mastitis; knowledge graph; traditional herbal medicine; drug

71 combination; clinical trial

72 Introduction

73	Plasma cell mastitis (PCM) represents as a serious inflammatory condition of
74	breast that occurs in young and middle-aged females at non-pregnant and non-
75	lactating period <sup>1</sup> . The main histopathological characteristics of PCM is the infiltration
76	of plasma cells and lymphocytes in breast tissue <sup>2</sup> . Interestingly, PCM shares similarity
77	with breast cancer in the perspective of macroscopical or microscopical
78	characteristics <sup>3</sup> . On the other hand, mounting evidences suggest that the dysregulation
79	of immune system is closely associated with the pathogenesis of PCM. Recently, the
80	incidence rate of PCM is quickly rising yet the treatment methods for PCM are still
81	rather limited. In clinical practice, surgical resection and hormone therapy remains as
82	two major treatments for PCM. Unfortunately, neither surgical resection nor hormone
83	therapy could prevent recurrence of PCM. Moreover, the serious side effects for
84	hormone therapy are still problematic <sup>4</sup> . Therefore, the discovery of effective PCM
85	treatment or therapeutics with minimal side effects is clearly warranted.
86	Traditional Chinese Medicine (TCM) has a rather long history for the prevention
87	and treatment of complex diseases in eastern Asia <sup>5-7</sup> . Moreover, for decades, TCM
88	has been often used as alternative or complementary medicine in the west. Indeed,
89	Chinese herbal compounds has been successfully applied in the treatment of plasma

90 cell mastitis (PCM) in conjunction with western medicine<sup>8</sup>. In clinical practice, TCM 91 refers to herbal entity prescription or formulae (also called as 'Fangji') which may 92 exhibit coordinating or synergistic effects through the combination of multiple herb 93 drugs<sup>9</sup>. However, the design of formulae in TCM is solely based on the principle of

94 'syndrome differentiation' according to the medicinal properties of herbal entities.
95 Moreover, the molecular mechanisms for the 'formulae' in TCM remains rather
96 elusive.

97 Knowledge graph has emerged as an advanced technology in the field of artificial 98 intelligence which is able to connect entities in a graph based on their existing intricate relationships<sup>10</sup>. In particular, knowledge graph can enable the rational design 99 100 and identification of combination therapies for a specific disease or phenotypes<sup>11</sup>. 101 Recently, we developed and constructed a knowledge graph for the discovery of 102 herbal drug combination towards immunotherapy and systematic immunity. 103 Subsequently, we identified a synergistic combination of herbal drugs for PCM via a 104 scoring system based on target hitting rates and phenotype relativeness. To verify our 105 concept of design, we conducted a clinical trial experiment for the drug combination 106 herbal compounds mentioned above (ClinicalTrials.gov of Registration: 107 NCT05530226). Strikingly, our clinical results demonstrated that the herbal drug 108 combination identified by knowledge graph can markedly suppress various 109 inflammatory cytokines in serum, restore clinical symptoms and reduce the recurrence 110 rates of PCM patients with improved global health status.

111 Results and Discussion

In previous study, we collected and compiled 240 targets for immunotherapy and systematic immunity from literature data<sup>12</sup>. Recently, we collected 345 entities of herbal drugs documented in TCM books and herbal drugs announced by National

115 Administration of Traditional Chinese Medicine through advanced text-mining 116 techniques. The existing intricate relationships between the herbal drugs and 117 immunotherapy targets were also extracted and compiled via advanced text-mining 118 techniques and manual curation for the construction of knowledge graph. We defined 119 an ontology list consisting of 13 ontology terms describing the relations (edges) 120 between herbal drug entities and the immunotherapy targets based on manual curation 121 of literature data (Supplemental Materials, Edge ontology terms). Moreover, we 122 collected the attributes of the medicinal properties for each herbal compound from Pharmacopoeia of China<sup>13</sup>. Totally, we compiled and integrated 64 attributes of the 123 124 medicinal properties for herbal drug entities into the knowledge graph (Supplemental 125 Materials, attributes of the medicinal properties). These medicinal properties are 126 useful throughout the design of herbal drug combination. Finally, we built the 127 knowledge graph via Neo4j and Py2Neo tools which consists of 895 nodes and 2197 128 edges (Figure 1 and Figure supplement 1), which can be visited online 129 (http://www.ikgg.org/).

Subsequently, we employed a scoring system (or so-called recommendation system) to asses and predict synergistic herbal drug combination from the knowledge graph. Of note, the scoring function is able to identify those herbal drug combinations that are most related with specific phenotypes as well as herbal drug combinations that are able to hit most discrete cellular targets, yet still following the principle of 'syndrome differentiation' as described in Pharmacopoeia of China (Materials and

136 Methods). To this end, we used this scoring function to select herbal drug 137 combinations consisting of eight herbal entities. We chose to identify drug 138 combinations with eight entities because 'formulae' consisting of eight drugs are 139 regarded as 'essence combination' in TCM community. In short, we employed a 140 combination generator that is able to randomly generate drug combinations with eight 141 herbal drug entities for ten rounds, each of which consists of 1,000 random drug 142 combinations. All the generated drug combinations from the ten rounds were further 143 ranked and evaluated. Noteworthy, the scoring results of the ten rounds presented as 144 normal distributions (Figure 2). The top twenty combinations from each round ranked 145 by the scoring function were further curated and inspected by experts in TCM. 146 Remarkably, we identified a specific drug combination which was ranked among top 147 twenty choices in all ten rounds of calculation. The combination consists of eight 148 herbal drug entities including 'Fructus forsythiae', 'Herba violae', 'Uniflower swisscentaury root', 'Danshen', 'Astragalus', 'Taraxacum', 'Liquorice' 149 and 150 'Honeysuckle' (see Figure 2).

Next, we extracted the subgraph for the herbal drug combination mentioned above and created a network diagram for the drug combination via Cytoscape tools<sup>14</sup> (**Figure 3**). In total, the eight herbal drug entities in the combination regulate 46 cellular targets related to immunotherapy and systematic immunity such as HIF-1, iNOS, IL-17, IL-6, IL-1 $\beta$ , mTOR, NLPR3, PD-L1, STAT3, TGF- $\beta$ , TLR2 and TLR4 etc. (**Figure 3**). Noteworthy, the medicinal properties of the eight drug entities could

157	be classified into three major categories of 'Heat-clearing and detoxicating', 'Qi-
158	tonifying' and 'Blood-activating menstruation regulating'. Moreover, we conducted
159	pathway analysis for the herbal drug combination for plasma cell mastitis.
160	Interestingly, we revealed that the herbal drug combination may modulate a few
161	pathways related to systematic immunity including 'Toll-like receptors cascades',
162	'MAP kinase activation', Adaptive immune system', 'Growth hormone receptor
163	signaling', 'Cytokine signaling in immune system' and 'Innate immune system' via
164	reactome knowledgebase <sup>15</sup> (Figure 4 and Supplemental Materials). We believe all
165	these may account for the therapeutic profiles of the herbal drug combination towards
166	PCM.

167 Subsequently, we want to evaluate the efficacy of herbal drug combination in 168 clinical trial for PCM patients (Clinicaltrials.gov number: NCT05530226). The 'Jun-169 Chen-Zuo-Shi' principle was examined for the herbal drug combination ('Formulae') 170 by TCM experts and the dosage for each drug entity from the drug combination was 171 adjusted by TCM experts. The clinical trial is a unrandomized, open label single arm study investigating the efficacy and safety of the herbal drug combination. To reveal 172 173 the therapeutic effects of TCM drug combination, we selected patients who were 174 treated with western medicine in the real world as comparison. Therefore, the two 175 groups of patients were divided into TCM treatment group (experimental group) and 176 western medicine treatment group (control group). All patients were diagnosed with 177 PCM by biopsy of breast tissue before recruited into the clinical trial. Patients in the

178	CG group (the control group) were orally treated with methylprednisolone whereas			
179	the patients in the EG group (the experimental or treatment group) were orally treated			
180	with herbal drug combination (Materials and Methods). Of note,			
181	methylprednisolone is a standard corticosteroid for the treatment of inflammatory			
182	conditions in clinical practice <sup>16</sup> and therefore methylprednisolone is used in the CG			
183	group.			

184 Efficacy was assessed every 2 cycles and the results were summarized after six 185 months of treatment. The baseline characteristics are shown in **Table S1**. Strikingly, 186 our results demonstrated that a few inflammatory cytokines in the serum including IL-187 2, IL-4, IL-6, IFN- $\gamma$ , IL-1 $\beta$  and TNF- $\alpha$  were significantly downregulated in PCM 188 patients after treatment of herbal drug combination as compared to the CG group 189 treated with methylprednisolone (Figure 5). We chose to measure these cytokines in 190 the experiments because they are often regarded as serum cytokine markers during the pathogenic development of PCM<sup>17</sup>. In addition, we found that serum level of IgA and 191 192 IgG level were markedly suppressed in the treatment group of herbal drug 193 combination as compared to the control group (Figure 6). Of note, both IgA and IgG have been found to be crucial diagnostic serum markers for PCM patients<sup>18</sup>. Moreover, 194 195 IgA is regarded as a major component of mucosal immunity which is closely related to the pathogenesis of PCM<sup>19,20</sup>. Therefore, our data suggests that the herbal drug 196 197 combination may enable the regulation of mucosal immunity and consequently 198 downregulate IgA and IgG serum level. Furthermore, we conducted the standard

199	Quality of Life questionnaire studies for PCM patients in the clinical experiment. Our
200	results implicated that symptom score, pain score and global health status of PCM
201	patients are significantly improved after treatment of the herbal drug combination as
202	compared to the control group (Figure 7). Noteworthy, our results demonstrated that
203	the recurrence rate of PCM patients in the treatment group were reduced to 3.75% as
204	compared to the recurrence rate of 12.5% in the control group (Table 1). Moreover,
205	the incidence rate of adverse events of PCM patients in the treatment group were
206	reduced to 6.25% as compared to the recurrence rate of 11.25% in the control group
207	(Table 1). In addition, we observed that the clinical symptoms of PCM patients in the
208	EG group such as swelling, abscess and fistula were reversed (Figure 8, Table_S2 in
209	Supplemental File) after treatment of herbal drug combinations. The clinical
210	symptom score in the EG group is ~4.68 as compared to the clinical symptom score of
211	$\sim$ 5.98 in the CG group (Table 2). These results suggest that the herbal drug
212	combination may achieve better efficacy for the treatment of PCM as compared to
213	methylprednisolone.

With the increasing amount of biomedical data, the traditional drug discovery campaign has been revolutionized with the aid of artificial intelligence techniques to accelerate the process and reduce the cost<sup>21</sup>. In recent years, knowledge graph, a technique that can provide structured relations among entities and unstructured semantic relations associated with entities, has been introduced into the domain of drug discovery<sup>11</sup>. Although the pathogenesis of PCM remains largely unclear, there

220 implicating have been numerous reports that the overactivation of immunoinflammatory pathways play an important role in the development of PCM<sup>22</sup>. 221 222 The major advantage of using Traditional Chinese Medicine is that herbal drug 223 combination can hit multiple discrete targets related to immunoinflammatory 224 pathways with improved efficacy and reduced toxicity. Herein, for the first time, we 225 showcase an example that identifies an herbal drug combination via knowledge graph 226 towards PCM. In contrast to using the conventional principle of 'syndrome 227 differentiation', our knowledge graph consisting of intricate relations between herbal 228 drug entities and immunotherapy targets coupled with scoring functions are able to 229 automatically identify novel herbal drug combinations which can hit most discrete 230 targets, making this strategy unique in the TCM community. Although we 231 acknowledge that the inclusion of chemical ingredients from the herbal drugs may 232 impact the outcome of our analysis and design, unfortunately, the inclusion of 233 chemical ingredients in the knowledge graph is rather technically difficult due to the 234 limited and incomplete datasets for the herbal drugs in the field of TCM. Nevertheless, 235 our strategy captures the prominent feature of design for drug combinations towards a 236 complex disease such as PCM. In the future, we plan to include multiple types of 237 omics data such as genomic, transcriptomic, proteomic, metagenomic or 238 metabolomics data into the knowledge graph to reveal novel targets and enable novel 239 drug discovery.

240	In the present study, our results revealed that the herbal drug combination
241	identified by knowledge graph could suppress a few key immunoinflammatory
242	cytokines, enhance the systematic immune levels and significantly reduce the
243	recurrence rates of PCM patients. Of note, recurrence has become one major obstacle
244	after surgical resection for PCM treatment in clinical practice. On the other hand,
245	hormone therapy may increase the risk of side effects for PCM patients. Therefore,
246	our approach of herbal drug combination may provide a new avenue for PCM
247	treatment with less recurrence rate and reduced incidence rate of adverse events.

#### 248 Conclusion

249 In summary, we report the identification and clinical assessment of an herbal drug 250 combination towards Plasma cell mastitis (PCM). We demonstrated that the herbal 251 drug combination holds great promise as an effective remedy for PCM, acting through 252 the regulation of immunoinflammatory pathways and improvement of systematic 253 immune level. In particular, the herbal drug combination could significantly reduce 254 the recurrence rate of PCM, a major obstacle for PCM treatment. Our data suggests 255 that the herbal drug combination is expected to feature prominently in the future PCM 256 treatment. Moreover, these promising results underscore the potential of knowledge 257 graph to identify drug combinations or other novel therapeutics across multiple types 258 of human disorders.

# 259 Acknowledgments

260	Y. Yang's laboratory was supported by the National Natural Science Foundation of
261	China (Grant: 81874301), the Fundamental Research Funds for Central University
262	(Grant: DUT22YG122) and the Key Research project of 'be Recruited and be in
263	Command' in Liaoning Province (Personal Target Discovery for Metabolic Diseases);
264	C. Liu's lab was supported by grants from the National Natural Science Foundation of
265	China (No. 81572609), China Medical University Major Construction Project (No.
266	2017ZDZX05) and Liaoning Colleges Innovative Talent Support Program (Cancer
267	Stem Cell Origin and Biological Behavior).

# 268 **Conflict of interest statement**

269 Ling Han is an employee of China Resources Sanjiu Medical & Pharmaceutical;
270 Manji Wang is an employee of Shanghai BeautMed Corporation.

# 271 Author Contributions

272 Q.Y., and G.C. performed data mining and data curation and constructed the 273 knowledge graph; Q.Y., Y.L. and Y.Y. designed the scoring system for the 274 knowledge graph; Q.Y., and Y.Y. participated in the design and styling of the web 275 interface; D.Z. helped to collect and analyze the medicinal properties of the herbal 276 drug entities; L.H. and N.N. participated in the design of herbal drug combination 277 product; M.W. and G.C. conducted analysis of clinical data and clinical pictures of 278 the PCM patients; H.Y. and N.N. coordinated the clinical trial experiments and

- 279 registration; C. L. and Y.Y. provided funding for the project; Y.Y. and C.L. initiated,
- 280 coordinated the whole project; Y.Y. wrote the manuscript.

# 281 **Declaration of Ethnics**

- 282 The protocol was approved by the Institutional Review Board (IRB) of the China
- 283 Medical University (approval number: 2021PS024T). This study was registered with
- 284 ClinicalTrials.gov: NCT05530226. All patients provided written informed consent.

285

### 286 Materials and Methods

#### 287 Construction of knowledge graph towards immunotherapy

288 We employed data mining techniques to collect and compile 240 targets of 289 immunotherapy and systematic immunity from PubMed database. Next, we collected 290 and compiled 345 herbal drug entities officially released by the National Health 291 Commission of China and National Administration of Traditional Chinese Medicine. 292 The intricate relations between the herbal drug entities and the immunotherapy targets 293 were extracted from the PubMed database. These intricate relations were subjected to 294 further manual curation. We used thirteen ontology terms (see Supplemental 295 Materials) to describe the intricate relations (edges) in the knowledge graph. 296 Moreover, 64 attributes of the medicinal properties for the herbal drug entities were 297 collected and compiled from Pharmacopoeia of China. Finally, we built the

knowledge graph via Neo4j and Py2Neo tools which consists of 895 nodes and 2197

edges.

# 300 Scoring system of the knowledge graph

301 To this end, we developed a scoring system to asses and predict synergistic drug

302 combination of herbal drug entities (number of drugs, n) as below,

303 
$$Score = f(x) * g(x) * \sum_{i=1}^{x} \left\| \begin{pmatrix} h_1 \\ h_2 \\ h_3 \end{pmatrix} \right\|$$
[1]

Herein, f(x) represents as the penalty function. f(x) value will be set to 0 if the medicinal properties of the drug combination fall into the contraindication rules in Pharmacopoeia of China. Otherwise, f(x) value will be set to 1.

307 
$$g(x) = 1 - p_i$$
 [2]

308 g(x) is the target diversity function as above and  $p_i$  is calculated as  $p_i = w/t$ ; t 309 refers to the total number of targets within the knowledge graph, w refers to the total 310 number of overlapping targets that the drug combination may hit. Hence, the target 311 diversity function can be used as a measure to assess the diversity of the targets that 312 the drug combination may hit. In another word, if each drug entity in the combination 313 hits distinct targets, the q(x) value will be set to 1. The last term of the scoring 314 system is used as a measure to assess the relativeness of each drug entity in the 315 combination and calculated as follows,

316 
$$\Sigma_{i=1}^{x} \left\| \begin{pmatrix} h_1 \\ h_2 \\ h_3 \end{pmatrix} \right\|$$
[3]

317 In brief,  $h_1$  represents the target hitting rates of each drug entity in the combination and was calculated as follows,  $h_1 = n_i/t$ ;  $n_i$  is the number of hitting targets for each 318 319 drug entity in the combination; Again, t refers to the total number of targets 320 constituting the knowledge graph for the disease; Noteworthy, the concept of hitting 321 rates towards discrete targets has been used in the scoring function for the selection of synergistic drug combinations<sup>23</sup>.  $h_2$  represents the phenotype relativeness of each 322 323 drug entity in the combination and  $h_2 = c_2 * 1/x$ , where x is the number of drug 324 entities in the combination and  $c_2$  is the parameter; Namely, if the drug entity is 325 related to the phenotype of the disease (co-occurrence with the disease phenotype in 326 the literature), then  $c_2$  value is set to 1 otherwise  $c_2$  value is set to 0;  $h_3$  represents the 327 literature relativeness or confidence of each drug entity in the combination and 328 calculated as follows,

329 
$$h_3 = c_3 * \log \sqrt{\sum_{i=1}^{x} l \times (j+k)}$$
 [4]

330 in which l is the number of studies/publications that validated the association of drug 331 entity with the specific disease (herein in the knowledge graph refers to cancer 332 immunotherapy), j and k refer to if the relations of the drug entity with the disease 333 have been validated in cell lines or patient (or animal) tissues, respectively. Namely, if 334 the drug entity was validated in cancer cell lines or patient tissues, the *j* or *k* value will 335 be set to 1, respectively. Otherwise, the j or k value will be set to 0;  $c_3$  is the parameter 336 and set to 1 here. Therefore, herein, a high score of  $h_3$  implicates that the drug 337 combination is more relevant to cancer immunotherapy with high confidence of

literature relativeness. Collectively, our scoring system can be used to select those
drug combinations that are most relevant with disease phenotypes and those drug
combinations that are able to hit most discrete targets related to immunotherapy.

341 Design of the clinical trial

342 In brief, 160 female patients diagnosed as plasma cell mastitis (PCM) in Shengjing 343 Hospital Affiliated to China Medical University were recruited in the clinical trial 344 between January 2021 to February 2022. Patients were randomly 1:1 divided into 345 experimental group (EG) and control group (CG). Noteworthy, in order to 346 demonstrate the therapeutic effect of TCM drug combination, we selected patients 347 who were treated with western medicine in the real world during the same period. 348 Therefore, the two groups of patients were divided into TCM treatment group 349 (experimental group) and western medicine treatment group (control group). There 350 was no significant difference in baseline data such as age, body mass index, clinical 351 classification, marriage and child-bearing history between the two groups 352 (Supplemental File, Table S1). Patients in the CG group were orally treated with 353 methylprednisolone tablets, 20mg/ day once a day. The patients in the EG group were 354 orally treated with 20g/bag of herbal drug combination twice a day, once in the 355 morning and once in the evening for 2 months. The herbal drug combination was 356 prepared as granules in the following formulae: Taraxacum 15g, Fructus forsythiae 357 15g, Honeysuckle 10g, Uniflower swisscentaury root 8g, Herba violae 20g, Danshen 358 10g, Astragalus 20g, Liquorice 8g. The herbal drug combination in the form of

359 granules was provided and prepared by Shengjing Hospital Affiliated to China360 Medical University.

## 361 Clinical trial protocol

- 362 The clinical trial for the herbal drug combination was registered at ClinicalTrials.gov
- and entitled as "A Single Arm Study of Traditional Chinese Medicine for Plasma Cell
- 364 Mastitis" with registration code of NCT05530226. The detailed clinical trial protocol
- 365 has been provided a separate document in the Supplemental Files named as
- 366 'PCM Clinical Protocol'.

#### 367 Measurement of serum inflammatory cytokines by ELSIA assay


- 368 Venous blood of the CG and EG groups were collected in sterile non-anticoagulant
- 369 test tube before and after treatment. The immune transmission turbidimetry was used
- 370 according to the procedure of CRP kit and automatic biochemical analyzer was used
- 371 to detect the level of CRP. The levels of serum cytokines were measured by ELISA
- 372 (Elabscience) according to the manufacturer's instructions.

## 373 Measurement of serum immunoglobulin level

The venous blood of PCM patients in the two groups were collected in sterile nonanticoagulant tube before and after treatment. The serum IgG and IgA were measured by rate scattering turbidimetry using Array 360 System automatic specific protein analyzer (Beckman Company, USA).

# 378 Assessment of clinical symptoms of PCM patients

- 379 The clinical symptoms were evaluated by attending physician with board certification
- 380 in pathology. The patients were scored before and after treatment according to the
- 381 standard rating scale for PCM (see Supplemental Materials).
- 382 Statistics
- 383 All data were evaluated as mean ± SEM. Statistical analysis of the quantitative
- 384 multiple group comparisons was performed using the one-way analysis of variance
- 385 (ANOVA) followed by Tukey's test; whereas pairwise comparisons were performed
- 386 using the t test by GraphPad Prism 8 (Graph Pad Software, La Jolla, CA, USA).
- 387 Results were considered to be statistically significant with p < 0.05.




398

Figure 1. Schematic diagram of the knowledge graph for the drug discovery ofplasma cell mastitis in the present work.




412 Figure 1 - Figure supplement 1. Snapshot of the medical knowledge graph towards
413 immunotherapy. The knowledge graph was constructed by Neo4j and Python tools
414 (http://www.ikgg.org/kghti).
415




- 416 417
- 418


Figure 2. The score statistics of ten rounds of random herbal drug combinations
(1,000 random combination from each round) for the treatment of plasma cell mastitis.
Noteworthy, the scoring results of the ten rounds presented as normal distributions.
The herbal drug combination identified for the clinical trial was among the top twenty
choices in all the ten rounds and marked in red dots.



435 Figure 3. Network diagram of the herbal drug combination consisting of eight entities 436 including 'Honeysuckle', 'Taraxacum', 'Astragalus', 'Danshen', 'Forsythia', 'Herba 437 violae', 'Liquorice' and 'Uniflower swisscentaury root' displayed in red circles. In 438 total, 46 cellular targets related to systemic immunity were hit by the drug 439 combination such as NLPR3, IL-17, TLR4, STAT3, IL-6, iNOS and TLR2 et al 440 which were displayed in green box model. Three major medicinal attributes 441 (properties) were identified for these herbal drug entities including 'Heat-clearing and 442 detoxicating', 'Qi-tonifying' and 'Blood-activating menstruation regulation'. 443



454 combination via reactome knowledgebase. The statistically significant pathways were 455 highlighted and displayed in yellow color (P<0.05).




462

463 **Figure 5.** The change of percentage for numerous immunological cytokines including 464 IL-2, IL-4, IL-6, IL-10, IL-17, CRP, IFN-γ, IL-1β and TNF-α from the control group 465 and the treatment group (with TCM treatment). Notably, a few key cytokines such as 466 IL-2, IL-4, IFN-γ, IL-1β and TNF-α were significantly downregulated in the 467 treatment group as compared to the control group.

468

469 Figure 5 – source data. Patients' raw data of serum cytokines from the control group
470 (without TCM treatment) and the treatment group (with TCM treatment) in the
471 clinical trial (ClinicalTrials.gov: NCT05530226).
472




479

480 Figure 6. The change of percentage for IgA level and IgG level from the control481 group and the treatment group (with TCM treatment).

482

Figure 6 – source data. Patients' raw data of serum IgA and IgG level from the
control group (without TCM treatment) and the treatment group (with TCM treatment)
in the clinical trial (ClinicalTrials.gov: NCT05530226).



494

495 Figure 7. The change of scores from items including symptom, pain and living
496 quality. The scores of symptoms, pain and living quality from the treatment group
497 were significantly improved as compared to the control group.

498

Figure 7 – source data 1. Patients' raw data of symptom scores from the control
group (without TCM treatment) and the treatment group (with TCM treatment) in the
clinical trial (ClinicalTrials.gov: NCT05530226).

Figure 7 – source data 2. Patients' raw data of pain scores from the control group
(without TCM treatment) and the treatment group (with TCM treatment) in the
clinical trial (ClinicalTrials.gov: NCT05530226).

505 **Figure 7** – **source data 3.** Patients' raw data of quality of life from the control group 506 (without TCM treatment) and the treatment group (with TCM treatment) in the 507 clinical trial (ClinicalTrials.gov: NCT05530226).




Figure 8. The comparison of whole breast for six representative PCM patients in the
EG group before treatment and after treatment (written informed consents have been
provided from all the patients).

- 522 Table 1. Comparison of operation rate, recurrence rate and incidence of adverse
- 523 reactions between the two groups (EG: experimental group; CG: control group).

524

Groups	nuns   Unergfinn   Recurrence		Incidence of adverse events	
EG	80	25 (31.25%)	3 (3.75%)	5 (6.25%)
CG	80	47 (58.75%)	10 (12.5%)	9 (11.25%)
<b>X</b> <sup>2</sup>		12.22	4.103	1.252
р		< 0.001	0.043	0.263

- 526 **Table 2.** Clinical symptom scores between the two groups in the clinical trial (EG:
- 527 experimental group; CG: control group; The clinical symptom rating scale for PCM
- 528 was displayed in Table\_S2 in the Supplemental File).

529

530

Groups	Ν	Baseline	Treated	t	р
	(Patients)				
EG	80	13.90±2.37	$4.68 \pm 3.40$	22.19	< 0.001
CG	80	13.423±2.70	$5.98 \pm 3.68$	14.282	< 0.001
t		1.189	2.323		
р		0.236	0.021		

531

### 533 References

533	References				
534					
535	1.	Cutler, M. Plasma-cell mastitis; report of a case with bilateral involvement. Br			
536		<i>Med J</i> <b>1</b> , 94-96 (1949).			
537	2.	Yu, J.J., et al. Mouse model of plasma cell mastitis. J Transl Med 10 Suppl 1,			
538		S11 (2012).			
539	3.	Cheng, L., et al. Mastitis, a Radiographic, Clinical, and Histopathologic			
540		Review. Breast J 21, 403-409 (2015).			
541	4.	Fleming, L., et al. The impact of medication side effects on adherence and			
542		persistence to hormone therapy in breast cancer survivors: A quantitative			
543		systematic review. Breast 64, 63-84 (2022).			
544	5.	Tu, Y. The discovery of artemisinin (qinghaosu) and gifts from Chinese			
545		medicine. Nat Med 17, 1217-1220 (2011).			
546	6.	Tu, Y. Artemisinin-A Gift from Traditional Chinese Medicine to the World			
547		(Nobel Lecture). Angew Chem Int Ed Engl 55, 10210-10226 (2016).			
548	7.	Yin, X., et al. Effect of Electroacupuncture on Insomnia in Patients With			
549		Depression: A Randomized Clinical Trial. JAMA Netw Open 5, e2220563			
550		(2022).			
551	8.	Zhang, J., Xu, J., Zhang, J. & Ren, Y. Chinese herbal compound combined			
552		with western medicine therapy in the treatment of plasma cell mastitis: A			
553		protocol for systematic review and meta-analysis. <i>Medicine (Baltimore)</i> 99,			
554	0	e22858 (2020).			
555	9.	Li, S., Zhang, B., Jiang, D., Wei, Y. & Zhang, N. Herb network construction			
556		and co-module analysis for uncovering the combination rule of traditional			
557 558	10	Chinese herbal formulae. <i>BMC Bioinformatics</i> <b>11 Suppl 11</b> , S6 (2010).			
558 559	10.	Ye, Q., <i>et al.</i> A unified drug-target interaction prediction framework based on knowledge graph and recommendation system. <i>Nat Commun</i> <b>12</b> , 6775 (2021).			
559 560	11.	Zeng, X., Tu, X., Liu, Y., Fu, X. & Su, Y. Toward better drug discovery with			
561	11.	knowledge graph. <i>Curr Opin Struct Biol</i> <b>72</b> , 114-126 (2022).			
562	12.	Zhang, Y., <i>et al.</i> Checkpoint therapeutic target database (CKTTD): the first			
563	12.	comprehensive database for checkpoint targets and their modulators in cancer			
564		immunotherapy. J Immunother Cancer 8(2020).			
565	13.	Hao, Y.F. & Jiang, J.G. Origin and evolution of China Pharmacopoeia and its			
566	15.	implication for traditional medicines. <i>Mini Rev Med Chem</i> <b>15</b> , 595-603 (2015).			
567	14.	Reimand, J., <i>et al.</i> Pathway enrichment analysis and visualization of omics			
568	1	data using g:Profiler, GSEA, Cytoscape and EnrichmentMap. <i>Nat Protoc</i> 14,			
569		482-517 (2019).			
570	15.	Jassal, B., et al. The reactome pathway knowledgebase. Nucleic Acids Res 48,			
571		D498-D503 (2020).			
572	16.	Lv, J., et al. Effect of Oral Methylprednisolone on Clinical Outcomes in			
573		Patients With IgA Nephropathy: The TESTING Randomized Clinical Trial.			
574		JAMA 318, 432-442 (2017).			

575	17.	Liu, Y., et al. Activation of the IL-6/JAK2/STAT3 pathway induces plasma
576		cell mastitis in mice. Cytokine 110, 150-158 (2018).
577	18.	Xing, M., Zhang, S., Zha, X. & Zhang, J. Current Understanding and
578		Management of Plasma Cell Mastitis: Can We Benefit from What We Know?
579		Breast Care (Basel) 17, 321-329 (2022).
580	19.	Betts, C.B., et al. Mucosal Immunity in the Female Murine Mammary Gland.
581		<i>J Immunol</i> <b>201</b> , 734-746 (2018).
582	20.	Bharathan, M. & Mullarky, I.K. Targeting mucosal immunity in the battle to
583		develop a mastitis vaccine. J Mammary Gland Biol Neoplasia 16, 409-419
584		(2011).
585	21.	Yang, Y., Adelstein, S.J. & Kassis, A.I. Target discovery from data mining
586		approaches. Drug Discov Today 14, 147-154 (2009).
587	22.	Liu, Y., et al. IL-6/STAT3 signaling pathway is activated in plasma cell
588		mastitis. Int J Clin Exp Pathol 8, 12541-12548 (2015).
589	23.	Jin, W., et al. Deep learning identifies synergistic drug combinations for
590		treating COVID-19. Proc Natl Acad Sci U S A 118(2021).
591		
592		